Aitia is highlighting that data from its Alzheimer's Disease Digital Twins platform will be presented at the upcoming Clinical Trials on Alzheimer's Disease (CTAD), being held from October 24 to 27 in Boston.
Aitia's Digital Twins are computational representations of disease that capture genetic and molecular interactions that causally drive clinical and physiological outcomes.
The presentation will focus on results from Alzheimer's Digital Twins derived from the GAP Bio-Hermes study, which evaluated biomarkers, surrogate markers, and cognitive tests and prioritizing diversity in the study protocol. Specifically, Aitia Gemini Digital Twins have yielded new levels of predictive accuracy of PET positivity across different ethnoracial groups and various disease stages. The research is titled, "Prediction of Amyloid PET positivity from blood-based biomarkers and clinical data using AI-based Digital Twins."
Aitia said these models could lead to better addressing of screen failure rates in clinical trial recruitment that affects Alzheimer's clinical trials. This method aims to be accessible to a broader at-risk population while also examining the role of various data sources in predicting PET positivity, the company added.
